Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Moleculin Biotech Q2 EPS $(1.70) Beats $(2.31) Estimate

Author: Benzinga Newsdesk | August 14, 2024 08:12am
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(2.31) by 26.41 percent. This is a 43.71 percent increase over losses of $(3.02) per share from the same period last year.

Posted In: MBRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist